Select a medication above to begin.
polynicotinate de chrome
chromium
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- antiretroviral-induced insulin resistance [Insufficient Evidence]
- athletic performance [Insufficient Evidence]
- binge eating disorder [Insufficient Evidence]
- bipolar disorder [Insufficient Evidence]
- chromium deficiency [Likely Effective]
- cognitive impairment, mild [Insufficient Evidence]
- depression [Insufficient Evidence]
- diabetes mellitus [Possibly Effective]
- dyslipidemia, beta blocker-related [Insufficient Evidence]
- HTN [Possibly Ineffective]
- hypoglycemia [Insufficient Evidence]
- hyperlipidemia [Insufficient Evidence]
- impaired glucose tolerance [Possibly Ineffective]
- metabolic syndrome [Insufficient Evidence]
- MI prevention [Insufficient Evidence]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- obesity [Insufficient Evidence]
- polycystic ovary syndrome [Insufficient Evidence]
- schizophrenia [Possibly Ineffective]
- Turner syndrome [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
antiretroviral-induced insulin resistance
- [Insufficient Evidence]
- Dose: 200 mcg chromium nicotinate PO qd; Alt: 1000 mcg chromium picolinate PO qd
athletic performance
- [Insufficient Evidence]
- Dose: 400 mcg chromium picolinate PO qd
bipolar disorder
- [Insufficient Evidence]
- Dose: 600-800 mcg chromium chloride PO qd
chromium deficiency, adult pts
- [Likely Effective]
- Dose: 25 mcg PO qd in female pts 19-50 yo; 20 mcg PO qd in female pts 51 yo and older; 35 mcg PO qd in male pts 19-50 yo; 30 mcg PO qd in male pts 51 yo and older; Info: based on established daily adequate intake levels
chromium deficiency, peds pts
- [Likely Effective]
- Dose: 0.2 mcg PO qd in pts 0-6 mo; 5.5 mcg PO qd in pts 7-12 mo; 11 mcg PO qd in pts 1-3 yo; 15 mcg PO qd in pts 4-8 yo; 21 mcg PO qd in female pts 9-13 yo; 24 mcg PO qd in female pts 14-18 yo; 25 mcg PO qd in male pts 9-13 yo; 35 mcg PO qd in male pts 14-18 yo; Info: based on established daily adequate intake levels
cognitive impairment, mild
- [Insufficient Evidence]
- Dose: 1000 mcg chromium picolinate PO qd
depression
- [Insufficient Evidence]
- Dose: 600 mcg chromium picolinate PO qd; Start: 400 mcg PO qd x2wk
diabetes mellitus
- [Possibly Effective]
- Dose: 42-1000 mcg/day PO divided qd-tid; Alt: 4-8 mcg/kg/day chromium picolinate PO qd
dyslipidemia, beta blocker-related
- [Insufficient Evidence]
- Dose: 200 mcg PO tid
hyperlipidemia, adult pts
- [Insufficient Evidence]
- Dose: 42-1000 mcg PO qd; Alt: 200 mcg chromium polynicotinate PO bid; 200 mcg chromium picolinate PO qd; 250 mcg chromium chloride PO qd
hyperlipidemia, peds pts
- [Insufficient Evidence]
- Dose: 400-600 mcg chromium polynicotinate PO bid
hypoglycemia
- [Insufficient Evidence]
- Dose: 200 mcg chromium chloride PO qd; Alt: 125 mcg chromium yeast PO qd
polycystic ovary syndrome
- [Insufficient Evidence]
- Dose: 200-1000 mcg/day chromium picolinate PO divided qd-tid
Turner syndrome
- [Insufficient Evidence]
- Dose: 50 mcg PO qd
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.